Shenzhen Hepalink Pharmaceutical Co Ltd (002399) — Net Asset Quality Index
Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has a Net Asset Quality Index of 71.9% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥17.01 Billion minus total liabilities of CN¥4.78 Billion yields net assets of CN¥12.23 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 002399 financial resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shenzhen Hepalink Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2006–2025)
This chart shows how Shenzhen Hepalink Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 20 annual periods from 2006 to 2025. As of March 2026, the index stands at 71.9%, representing net assets of CN¥12.23 Billion against total assets of CN¥17.01 Billion CNY. See 002399 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)
The table below presents the year-by-year Net Asset Quality Index for Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025, covering 20 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 002399 market cap.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 72.6% | CN¥12.08 Billion | CN¥16.63 Billion | CN¥4.55 Billion | ▲ +2.3 pp |
| 2024 | 70.4% | CN¥12.20 Billion | CN¥17.34 Billion | CN¥5.14 Billion | ▲ +7.9 pp |
| 2023 | 62.4% | CN¥11.99 Billion | CN¥19.20 Billion | CN¥7.22 Billion | ▲ +2.8 pp |
| 2022 | 59.6% | CN¥12.41 Billion | CN¥20.81 Billion | CN¥8.41 Billion | ▼ -0.7 pp |
| 2021 | 60.3% | CN¥11.52 Billion | CN¥19.11 Billion | CN¥7.58 Billion | ▼ -1.1 pp |
| 2020 | 61.4% | CN¥11.69 Billion | CN¥19.03 Billion | CN¥7.34 Billion | ▲ +12.4 pp |
| 2019 | 49.0% | CN¥7.47 Billion | CN¥15.24 Billion | CN¥7.77 Billion | ▲ +3.3 pp |
| 2018 | 45.7% | CN¥6.24 Billion | CN¥13.66 Billion | CN¥7.41 Billion | ▼ -12.5 pp |
| 2017 | 58.3% | CN¥7.69 Billion | CN¥13.19 Billion | CN¥5.50 Billion | ▼ -4.4 pp |
| 2016 | 62.6% | CN¥8.09 Billion | CN¥12.91 Billion | CN¥4.83 Billion | ▼ -9.6 pp |
| 2015 | 72.3% | CN¥8.79 Billion | CN¥12.17 Billion | CN¥3.38 Billion | ▼ -11.9 pp |
| 2014 | 84.1% | CN¥8.35 Billion | CN¥9.93 Billion | CN¥1.58 Billion | ▼ -13.4 pp |
| 2013 | 97.5% | CN¥8.07 Billion | CN¥8.27 Billion | CN¥203.80 Million | ▲ +0.1 pp |
| 2012 | 97.4% | CN¥8.05 Billion | CN¥8.26 Billion | CN¥214.53 Million | ▼ -1.8 pp |
| 2011 | 99.2% | CN¥7.91 Billion | CN¥7.97 Billion | CN¥59.98 Million | ▲ +0.5 pp |
| 2010 | 98.7% | CN¥8.02 Billion | CN¥8.13 Billion | CN¥103.44 Million | ▲ +21.0 pp |
| 2009 | 77.7% | CN¥1.07 Billion | CN¥1.38 Billion | CN¥306.33 Million | ▲ +24.6 pp |
| 2008 | 53.2% | CN¥307.83 Million | CN¥578.92 Million | CN¥271.09 Million | ▼ -3.6 pp |
| 2007 | 56.8% | CN¥146.44 Million | CN¥257.73 Million | CN¥111.28 Million | ▲ +30.7 pp |
| 2006 | 26.2% | CN¥91.33 Million | CN¥349.01 Million | CN¥257.68 Million | — |